<b>Conclusion:</b> This study demonstrates the potential of RBC-conjugated biomimetic nanomedicine as a promising strategy for enhancing the treatment efficiency of EGFR-TKI against NSCLC <i>in vivo</i>. This evidence concerns the gene EGFR and non-small cell lung carcinoma.